Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDIV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 448Melanoma 287Squamous Cell Carcinoma of Head and Neck 229Parkinson Disease 4, Autosomal Dominant Lewy Body 188Neoplasms 180Breast Neoplasms 161Triple Negative Breast Neoplasms 160Neoplasm Metastasis 155Lung Neoplasms 140Colorectal Neoplasms 140Carcinoma, Renal Cell 129Head and Neck Neoplasms 120Stomach Neoplasms 103Ovarian Neoplasms 100Carcinoma, Transitional Cell 91Urinary Bladder Neoplasms 80Pancreatic Neoplasms 80Endometrial Neoplasms 72Carcinoma, Hepatocellular 72Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 48Sarcoma 43Carcinoma 42Glioblastoma 39Carcinoma, Squamous Cell 39Small Cell Lung Carcinoma 38Hodgkin Disease 36Lymphoma 34

Interventions

pembrolizumab 1SH-1028 1Injections 12-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-5-(2-hydroxy-3-morpholinopropyl)-3-methyl-5,6,7,8-tetrahydro-1H-pyrrolo(3,2-c)azepin-4-ketone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Solid Cancer × pembrolizumab × Clear all
NCT07123415 2025-11-19

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Aptabio Therapeutics, Inc.

Phase 1 Recruiting
110 enrolled
Other solid neoplasm

Advanced Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡